Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lymphoproliferative Disorders in Multiple Primary Cancers

  • Demirci, Umut (Ataturk Education and Research Hospital, Gazi University) ;
  • Ozdemir, Nuriye (Numune Education and Research Hospital, Department of Medical Oncology, Gazi University) ;
  • Benekli, Mustafa (Faculty of Medicine, Department of Medical Oncology, Gazi University) ;
  • Babacan, Nalan Akgul (Numune Education and Research Hospital, Department of Medical Oncology, Gazi University) ;
  • Cetin, Bulent (Faculty of Medicine, Department of Medical Oncology, Gazi University) ;
  • Baykara, Meltem (Faculty of Medicine, Department of Medical Oncology, Gazi University) ;
  • Coskun, Ugur (Faculty of Medicine, Department of Medical Oncology, Gazi University) ;
  • Zengin, Nurullah (Numune Education and Research Hospital, Department of Medical Oncology, Gazi University) ;
  • Buyukberber, Suleyman (Faculty of Medicine, Department of Medical Oncology, Gazi University)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Cancer survivors are at increased risk of second cancers. Lymphoproliferative disorders (LPD) are common neoplasms that are primary or subsequent cancers in cases of multiple primary cancer. We here analyzed metachronous or synchronous LPD in multiple primary cancers. Methods: Between 2001 and 2010, LPD were assessed retrospectively in 242 multiple primary cancers patients. Results: Forty nine (20.2%) patients with LPD were detected. Six patients had two LPD where one patient had three LPD. The median age of patients was 60.5 years (range: 28-81). LPD were diagnosed in 29 patients as primary cancer, in 23 patients as second cancer, and in three patients as third cancer in multiple primary cancers. Primary tumor median age was 56 (range: 20-79). Diffuse large B cell lymphoma (n=16), breast cancer (n=9), and lung cancer (n=6) were detected as subsequent cancers. Alklylating agents were used in 19 patients (43.2%) and 20 patients (45.5%) had received radiotherapy for primary cancer treatment. The median follow-up was 70 months (range: 7-284). Second malignancies were detected after a median of 51 months (range: 7-278), and third malignancies with a median of 18 months (range: 6-72). Conclusions: In this study, although breast and lung cancer were the most frequent detected solid cancers in LPD survivors, diffuse large B cell lymphoma was the most frequent detected LPD in multiple primary cancers.

Keywords

References

  1. Armitage JO. (2000) Myelodysplasia and acute leukemia after autologous bone marrow transplantation. J Clin Oncol, 18, 945-6. https://doi.org/10.1200/JCO.2000.18.5.945
  2. Bassal M, Mertens AC, Taylor L, et al (2006). Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol, 24, 476-83. https://doi.org/10.1200/JCO.2005.02.7235
  3. Brennan P, Scelo G, Hemminki K, et al (2005). Second primary cancers among 109.000 cases of non-Hodgkin's lymphoma. Br J Cancer, 93, 159. https://doi.org/10.1038/sj.bjc.6602654
  4. Chaturvedi AK, Engels EA, Gilbert ES, et al (2007). Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst, 99, 1634-43. https://doi.org/10.1093/jnci/djm201
  5. Cardous Ubbink MC, Heinen RC, Bakker PJ, et al (2007). Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer, 43, 351-62. https://doi.org/10.1016/j.ejca.2006.10.004
  6. Demirci U, Bugdayci F, Cakir A, et al (2010). Bilateral breast cancer in a survivor of acute lymphoblastic leukemia: a case report. Med Oncol, 27, 481-3. https://doi.org/10.1007/s12032-009-9238-4
  7. De Vathaire F, Hawkins M, Campbell S, et al (1999). Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer, 79, 1884-93. https://doi.org/10.1038/sj.bjc.6690300
  8. Dong C, Hemminki K (2001). Second primary neoplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer, 85, 997-1005. https://doi.org/10.1054/bjoc.2001.1998
  9. Dores GM, Metayer C, Curtis RE, et al (2002). Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol, 20, 3484-94. https://doi.org/10.1200/JCO.2002.09.038
  10. Dores GM, Cote TR, Travis LB (2006). New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma and myeloma. In: Curtis R, Freedman D, Ron F et al., eds. New malignancies among cancer survivors: SEER cancer registries, 1973-2000 (NIH Publ. No: 05-5302). 397, National Institutes of Health, Bethesda MD.
  11. Hisada M, Chen BE, Jaffe ES, Travis LB (2007). Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst, 99, 215-22. https://doi.org/10.1093/jnci/djk030
  12. Hodgson DC, Gilbert ES, Dores GM, et al (2007). Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol, 25, 1489-97. https://doi.org/10.1200/JCO.2006.09.0936
  13. Ganz PA (2001). Late effects of cancer and its treatment. Semin Oncol Nurs, 17, 241-8. https://doi.org/10.1053/sonu.2001.27914
  14. Jenkinson HC, Hawkins MM, Stiller CA, et al (2004). Longterm population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer, 91, 1905-10. https://doi.org/10.1038/sj.bjc.6602226
  15. Krishnan B, Morgan GJ (2007). Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomarkers Prev, 16, 377-80. https://doi.org/10.1158/1055-9965.EPI-06-1069
  16. Meadows AT, Friedman DL, Neglia JP, et al (2009). Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol, 27, 2356-62. https://doi.org/10.1200/JCO.2008.21.1920
  17. Neglia JP, Maedows AT, Robison LL, et al (1991). Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med, 325, 1330-6. https://doi.org/10.1056/NEJM199111073251902
  18. Neglia JP, Friedman DL, Yasui Y, et al (2001). Second malignant neoplasms in five-year survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst, 93, 618-29. https://doi.org/10.1093/jnci/93.8.618
  19. Ng AK, Travis LB (2008) Subsequent malignant neoplasms in cancer survivors. Cancer J, 14, 429-34. https://doi.org/10.1097/PPO.0b013e31818d8779
  20. Olsen JH, Garwicz S, Hertz H, et al (1993). Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ, 307, 1030-6. https://doi.org/10.1136/bmj.307.6911.1030
  21. Ries L, Eisner M, Kosary C, et al (2006). SEER cancer statistics review. 1975-2003. National Cancer Institute, Bethesda MD.
  22. Swerdlow SH, Campo E, Harris NL, et al (2008). In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, 12-13, Lyon, IARC Pres.
  23. Travis LB, Curtis RE, Glimelius B, et al (1993). Second cancers among long-term survivors of non-Hodgkin's disease. J Natl Cancer Inst, 85, 1932-7. https://doi.org/10.1093/jnci/85.23.1932
  24. Travis LB, Curtis Re, Glimelius B, et al (1995). Bladder and kidney cancer following cyclophosphomide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst, 87, 524. https://doi.org/10.1093/jnci/87.7.524
  25. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK (2006). The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107, 108-15. https://doi.org/10.1002/cncr.21971

Cited by

  1. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Diagnosis of Lymphoma vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4169
  2. Type Distribution of Lymphomas in Lebanon: Five-Year Single Institution Experience vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5825
  3. Lung cancer and concurrent or sequential lymphoma: Two case reports with hypersensitivity to bevacizumab and a review of the literature pp.1792-1082, 2014, https://doi.org/10.3892/ol.2014.2717
  4. Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma vol.8, pp.1, 2018, https://doi.org/10.1038/s41408-017-0043-6
  5. One Pulmonary Lesion, 2 Synchronous Malignancies vol.6, pp.2324-7096, 2018, https://doi.org/10.1177/2324709618785934